Kazia Therapeutics – introducing novel asset EVT-801

Published on 22 October 2021

Kazia Therapeutics is an oncology focused drug development company based in Sydney, Australia. In addition to Kazia’s lead programme, paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway developed to treat the most common form of brain cancer, the company is developing EVT-801, a small molecule inhibitor of VEGFR3. Preclinical data have shown EVT-801 to be active against a broad range of tumor types.

In this video, Dr James Garner, CEO of Kazia, discusses the rationale behind acquiring the asset, the company’s plans for a Phase I trial and what investors can expect over the next year.

Share this with friends and colleagues